Alternative Palbociclib Dosing Schedules for Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer
Dosing schedules other than the standard 3/1 schedule can be used to continue palbociclib with HR+/HER2-MBC while ensuring therapeutic efficacy. Alternative dosing schedules look promising and need further research (preferably, prospective studies) with a larger sample size and longer follow-up to validate treatment efficacy.
Authors
- Tomoaki Yoshimura (ORCID: https://orcid.org/0009-0008-2486-8169)
- M Kimura (ORCID: https://orcid.org/0000-0002-7661-9841)
- Shiori Yamada
- Makiko Go (ORCID: https://orcid.org/0009-0001-6499-7060)
- Eiseki Usami (ORCID: https://orcid.org/0000-0002-3422-3072)
- Keitaro Kamei
- Yoshinori Noguchi (ORCID: https://orcid.org/0000-0002-9110-9604)
Institutions
- Gifu Pharmaceutical University (JP)
- Gifu University of Medical Science (JP)
- Ogaki Municipal Hospital (JP)
Publication Details
- Journal
- Oncology
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1159/000542991
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00